What's breaking now, across thousands of outlets.
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
We haven't written up this one. NPR Health has the full story — the link below goes straight to it.
People with Alpha-Gal Syndrome can have allergic reactions to meat from mammals. Many of those affected change their diets to eat other proteins.
The center will study the long-term impact of infections, in addition to RFK Jr.'s focus on vaccines.
Moderna's CEO Stéphane Bancel on what's next after the recent success in cancer vaccine, and how that impacts the company's business strategy.
One in 10 adults in Korea used or was prescribed obesity drugs such as Wegovy and Mounjaro in the past year, with younger generations reporting higher usage and one-third of respondents saying they…
Bayer receives green light in China for new stroke protection. Asundexian is the first drug of a new class of anticoagulants approved there.
Zhejiang Wenda Pharma published Phase II clinical trial results at ESMO 2026 for oral BET inhibitor NHWD 870 HCl in patients with advanced NUT carcinoma
